Cardio Vascu-Grow minimizes effects of stroke

Not only was the area affected by stroke minimized, the treated animals had significantly less neurological defects as assessed by several behavioral tests. In theory, this could indicate improvement in the recovery of lost brain function in stroke patients due to a reduction in size of the stroke-affected brain tissue area.

Stroke is the third major cause of death in the United States. It is reported by the American Heart Association (AHA) that each year about 700,000 people experience a new or recurrent stroke in the US. The cost to treat and care for the nearly five million stroke patients in the US was $53.6 billion in 2004. The AHA believes the majority of strokes to be caused by a lack of blood flow to the brain which is often due to clogged or blocked arteries

CardioVascular BioTherapeutics (CVBT) is currently conducting clinical trials in which the drug is being administered to patients that have clogged or blocked coronary arteries, causing diminished blood flow to portions of the heart. Although the results of these trials have not yet been released, the company has said it is pleased with progress to date.

Daniel Montano, president of CVBT said: “The most important thing about these pre-clinical results is the potential impact of our drug candidate on the mortality and quality of life of the millions of stroke victims in the United States. Secondly is the economic impact on payors. If CVBT’s drug candidate can reduce the damaged area of the brain from a stroke, sufferers of a stroke might be able to have a more normal life resulting in reduced medical care requirements over the rest of their lives. This could result in a material cost reduction in medical care for stroke victims.”